Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen

Trial Profile

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Aprepitant (Primary) ; Ondansetron
  • Indications Radiotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms AVERT
  • Most Recent Events

    • 02 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 28 Dec 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
    • 28 Dec 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top